vs

Side-by-side financial comparison of ISABELLA BANK CORP (ISBA) and AVITA Medical, Inc. (RCEL). Click either name above to swap in a different company.

ISABELLA BANK CORP is the larger business by last-quarter revenue ($21.2M vs $17.6M, roughly 1.2× AVITA Medical, Inc.). ISABELLA BANK CORP runs the higher net margin — 22.2% vs -66.0%, a 88.1% gap on every dollar of revenue. On growth, ISABELLA BANK CORP posted the faster year-over-year revenue change (14.3% vs -4.3%). ISABELLA BANK CORP produced more free cash flow last quarter ($23.3M vs $-6.1M). Over the past eight quarters, AVITA Medical, Inc.'s revenue compounded faster (26.0% CAGR vs 12.6%).

The Bank of the Philippine Islands is a universal bank in the Philippines. It is the oldest bank in both the Philippines and Southeast Asia. It is the fourth largest bank in terms of assets, the second largest bank in terms of market capitalization, and one of the most profitable banks in the Philippines.

Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East...

ISBA vs RCEL — Head-to-Head

Bigger by revenue
ISBA
ISBA
1.2× larger
ISBA
$21.2M
$17.6M
RCEL
Growing faster (revenue YoY)
ISBA
ISBA
+18.6% gap
ISBA
14.3%
-4.3%
RCEL
Higher net margin
ISBA
ISBA
88.1% more per $
ISBA
22.2%
-66.0%
RCEL
More free cash flow
ISBA
ISBA
$29.4M more FCF
ISBA
$23.3M
$-6.1M
RCEL
Faster 2-yr revenue CAGR
RCEL
RCEL
Annualised
RCEL
26.0%
12.6%
ISBA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ISBA
ISBA
RCEL
RCEL
Revenue
$21.2M
$17.6M
Net Profit
$4.7M
$-11.6M
Gross Margin
81.2%
Operating Margin
32.2%
-59.1%
Net Margin
22.2%
-66.0%
Revenue YoY
14.3%
-4.3%
Net Profit YoY
17.4%
-0.3%
EPS (diluted)
$0.64
$-0.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ISBA
ISBA
RCEL
RCEL
Q4 25
$21.2M
$17.6M
Q3 25
$20.5M
$17.1M
Q2 25
$18.8M
$18.4M
Q1 25
$18.1M
$18.5M
Q4 24
$18.5M
$18.4M
Q3 24
$18.0M
$19.5M
Q2 24
$17.2M
$15.2M
Q1 24
$16.7M
$11.1M
Net Profit
ISBA
ISBA
RCEL
RCEL
Q4 25
$4.7M
$-11.6M
Q3 25
$5.2M
$-13.2M
Q2 25
$5.0M
$-9.9M
Q1 25
$3.9M
$-13.9M
Q4 24
$4.0M
$-11.6M
Q3 24
$3.3M
$-16.2M
Q2 24
$3.5M
$-15.4M
Q1 24
$3.1M
$-18.7M
Gross Margin
ISBA
ISBA
RCEL
RCEL
Q4 25
81.2%
Q3 25
81.3%
Q2 25
81.2%
Q1 25
84.7%
Q4 24
87.6%
Q3 24
83.7%
Q2 24
86.1%
Q1 24
86.4%
Operating Margin
ISBA
ISBA
RCEL
RCEL
Q4 25
32.2%
-59.1%
Q3 25
30.7%
-53.6%
Q2 25
32.8%
-60.5%
Q1 25
26.9%
-63.9%
Q4 24
26.0%
-54.1%
Q3 24
21.3%
-70.6%
Q2 24
23.9%
-102.8%
Q1 24
21.8%
-155.0%
Net Margin
ISBA
ISBA
RCEL
RCEL
Q4 25
22.2%
-66.0%
Q3 25
25.6%
-77.3%
Q2 25
26.7%
-53.9%
Q1 25
21.9%
-74.9%
Q4 24
21.6%
-63.0%
Q3 24
18.2%
-82.9%
Q2 24
20.3%
-101.3%
Q1 24
18.7%
-168.0%
EPS (diluted)
ISBA
ISBA
RCEL
RCEL
Q4 25
$0.64
$-0.37
Q3 25
$0.71
$-0.46
Q2 25
$0.68
$-0.38
Q1 25
$0.53
$-0.53
Q4 24
$0.54
$-0.44
Q3 24
$0.44
$-0.62
Q2 24
$0.46
$-0.60
Q1 24
$0.42
$-0.73

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ISBA
ISBA
RCEL
RCEL
Cash + ST InvestmentsLiquidity on hand
$26.0M
$18.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$231.4M
$-16.6M
Total Assets
$2.2B
$56.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ISBA
ISBA
RCEL
RCEL
Q4 25
$26.0M
$18.2M
Q3 25
$161.3M
$23.3M
Q2 25
$108.6M
$15.7M
Q1 25
$69.2M
$25.8M
Q4 24
$24.5M
$35.9M
Q3 24
$27.4M
$44.4M
Q2 24
$23.6M
$54.1M
Q1 24
$25.2M
$68.2M
Stockholders' Equity
ISBA
ISBA
RCEL
RCEL
Q4 25
$231.4M
$-16.6M
Q3 25
$227.4M
$-6.7M
Q2 25
$220.5M
$-12.9M
Q1 25
$215.6M
$-4.6M
Q4 24
$210.3M
$4.5M
Q3 24
$213.0M
$12.2M
Q2 24
$202.2M
$23.9M
Q1 24
$200.7M
$32.6M
Total Assets
ISBA
ISBA
RCEL
RCEL
Q4 25
$2.2B
$56.4M
Q3 25
$2.3B
$63.7M
Q2 25
$2.2B
$58.1M
Q1 25
$2.1B
$69.6M
Q4 24
$2.1B
$79.7M
Q3 24
$2.1B
$81.1M
Q2 24
$2.1B
$87.8M
Q1 24
$2.1B
$97.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ISBA
ISBA
RCEL
RCEL
Operating Cash FlowLast quarter
$26.8M
$-5.4M
Free Cash FlowOCF − Capex
$23.3M
$-6.1M
FCF MarginFCF / Revenue
110.2%
-34.7%
Capex IntensityCapex / Revenue
16.4%
3.8%
Cash ConversionOCF / Net Profit
5.72×
TTM Free Cash FlowTrailing 4 quarters
$36.0M
$-33.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ISBA
ISBA
RCEL
RCEL
Q4 25
$26.8M
$-5.4M
Q3 25
$2.7M
$-5.2M
Q2 25
$7.8M
$-10.2M
Q1 25
$4.7M
$-10.3M
Q4 24
$19.6M
$-8.1M
Q3 24
$3.6M
$-7.2M
Q2 24
$5.5M
$-12.8M
Q1 24
$3.4M
$-20.9M
Free Cash Flow
ISBA
ISBA
RCEL
RCEL
Q4 25
$23.3M
$-6.1M
Q3 25
$1.7M
$-6.2M
Q2 25
$7.2M
$-10.8M
Q1 25
$3.7M
$-10.5M
Q4 24
$17.5M
$-9.7M
Q3 24
$3.2M
$-11.0M
Q2 24
$5.1M
$-15.4M
Q1 24
$2.6M
$-22.0M
FCF Margin
ISBA
ISBA
RCEL
RCEL
Q4 25
110.2%
-34.7%
Q3 25
8.5%
-36.1%
Q2 25
38.5%
-58.4%
Q1 25
20.6%
-56.9%
Q4 24
94.6%
-52.7%
Q3 24
17.7%
-56.1%
Q2 24
29.8%
-101.6%
Q1 24
15.7%
-198.2%
Capex Intensity
ISBA
ISBA
RCEL
RCEL
Q4 25
16.4%
3.8%
Q3 25
5.0%
5.5%
Q2 25
3.2%
2.8%
Q1 25
5.5%
1.2%
Q4 24
11.4%
8.8%
Q3 24
2.0%
19.2%
Q2 24
2.4%
17.5%
Q1 24
4.9%
10.3%
Cash Conversion
ISBA
ISBA
RCEL
RCEL
Q4 25
5.72×
Q3 25
0.52×
Q2 25
1.56×
Q1 25
1.19×
Q4 24
4.91×
Q3 24
1.08×
Q2 24
1.59×
Q1 24
1.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons